GlassScriptPhysician profile
Charles Jordan Beach
NPI 1033848338
$3,975.43
in general payments reported to CMS, 2019-2025
26 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $567 · 2024: $1,748 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,737 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.68 |
| Education | $238.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $667.14 | 2023-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $454.33 | 2023-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $396.31 | 2024-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $379.53 | 2023-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $314.93 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $283.43 | 2023-2025 | Rayaldee |
| Lilly USA, LLC | $260.20 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $215.88 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $215.43 | 2023-2025 | Jynarque |
| Ardelyx, INC. | $157.62 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $117.40 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $79.69 | 2024-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $77.24 | 2024-2025 | Tarpeyo |
| Chiesi USA, INC. | $57.11 | 2023-2024 | Elfabrio |
| Novo Nordisk INC | $44.03 | 2025 | Ozempic |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $43.31 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $36.87 | 2024 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $32.56 | 2023-2025 | Gattex |
| Renalytix Ai, INC. | $21.07 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ascendis Pharma Endocrinology INC | $20.87 | 2025 | Yorvipath |
| Ani Pharmaceuticals, INC. | $18.55 | 2023 | Purified Cortrophin Gel |
| Nxstage Medical, INC. | $17.95 | 2025 | Liberty Select Cycler, Nxstage System One |
| Genentech USA, INC. | $17.15 | 2025 | Gazyva |
| Shield Therapeutics INC | $16.80 | 2023 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.56 | 2023 | Jardiance |
| Horizon Therapeutics Plc | $13.47 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.